Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

NRIX

Nurix Therapeutics Inc

Apr 16 • 04:00PM ET

14.65

Dollar change -0.81
Percentage change -5.24	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: ARKG VTI IWM VXF IWN IBB DWAS SCHA LABU VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.65	Insider Own	7.90%	Shs Outstand	48.72M	Perf Week	-16.19%
Market Cap	720.05M	Forward P/E	-	EPS next Y	-3.32	Insider Trans	-0.79%	Shs Float	45.27M	Perf Month	12.00%
Income	-144.73M	PEG	-	EPS next Q	-0.70	Inst Own	88.63%	Short Float	15.39%	Perf Quarter	68.00%
Sales	80.89M	P/S	8.90	EPS this Y	-14.58%	Inst Trans	-5.49%	Short Ratio	7.49	Perf Half Y	129.98%
Book/sh	3.43	P/B	4.27	EPS next Y	-9.44%	ROA	-42.39%	Short Interest	6.97M	Perf Year	19.89%
Cash/sh	4.96	P/C	2.95	EPS next 5Y	-	ROE	-65.37%	52W Range	4.22 - 18.12	Perf YTD	41.96%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-59.00%	ROI	-75.94%	52W High	-19.15%	Beta	2.00
Dividend TTM	-	Quick Ratio	2.86	Sales past 5Y	27.29%	Gross Margin	82.24%	52W Low	247.16%	ATR (14)	1.39
Dividend Ex-Date	-	Current Ratio	2.86	EPS Y/Y TTM	24.89%	Oper. Margin	-194.51%	RSI (14)	51.45	Volatility	12.98% 9.59%
Employees	284	Debt/Eq	0.17	Sales Y/Y TTM	94.02%	Profit Margin	-178.93%	Recom	1.36	Target Price	25.09
Option/Short	Yes / Yes	LT Debt/Eq	0.13	EPS Q/Q	-0.31%	Payout	-	Rel Volume	1.39	Prev Close	15.46
Sales Surprise	-3.20%	EPS Surprise	2.01%	Sales Q/Q	30.74%	Earnings	Apr 10 BMO	Avg Volume	930.49K	Price	14.65
SMA20	1.26%	SMA50	16.11%	SMA200	58.27%	Trades		Volume	1,289,651	Change	-5.24%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-26-23	Resumed	Oppenheimer	Outperform	$25
Mar-09-23	Initiated	Barclays	Overweight	$20
Feb-28-23	Initiated	Oppenheimer	Outperform	$25
Oct-11-22	Initiated	Morgan Stanley	Equal-Weight	$11
May-31-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$25
Feb-10-22	Initiated	Wells Fargo	Equal Weight	$28
Dec-29-21	Initiated	H.C. Wainwright	Buy	$62
Oct-14-21	Initiated	SVB Leerink	Outperform	$50
Jun-04-21	Resumed	Robert W. Baird	Outperform	$45 → $46
Apr-30-21	Resumed	Piper Sandler	Overweight	$60
Apr-30-21	Initiated	RBC Capital Mkts	Outperform	$42
Apr-14-21	Initiated	Berenberg	Buy
Nov-19-20	Initiated	Robert W. Baird	Outperform	$40
Aug-18-20	Initiated	Stifel	Buy	$34
Aug-18-20	Initiated	Piper Sandler	Overweight	$40
Aug-18-20	Initiated	Needham	Buy	$35
Aug-18-20	Initiated	JP Morgan	Overweight	$35

Show Previous Ratings

Apr-11-24 11:38PM	Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering (GlobeNewswire) +9.69%
04:00PM	Nurix Therapeutics Announces Proposed Public Offering (GlobeNewswire)
Apr-10-24 11:53AM	NRIX Stock Earnings: Nurix Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -10.24%
09:29AM	Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study (Zacks)
08:31AM	Nurix Therapeutics Inc (NRIX) Misses Earnings Predictions But Shows Revenue Growth in Q1 Fiscal 2024 (GuruFocus.com)
08:10AM	Loading…
08:10AM	Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-09-24 01:15PM	Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies (GlobeNewswire) +26.67%
07:00AM	Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6 (GlobeNewswire)
Apr-03-24 07:00AM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-02-24 07:00AM	Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences (GlobeNewswire)
Mar-25-24 07:00AM	Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD) (GlobeNewswire)
Mar-20-24 09:40AM	Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting (GlobeNewswire)
Mar-11-24 07:00AM	Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial (GlobeNewswire)
Mar-06-24 04:00PM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +17.39%
04:30PM	Loading…
Mar-05-24 04:30PM	Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting (GlobeNewswire)
Feb-23-24 06:20AM	Nurix Therapeutics, Inc. (NRIX) Surges 5.1%: Is This an Indication of Further Gains? (Zacks)
Feb-16-24 07:04PM	Nurix Therapeutics Inc (NRIX) Reports Robust Year-End Financials and Clinical Progress (GuruFocus.com)
Feb-15-24 05:10PM	Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +6.95%
04:00PM	Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-01-24 04:01PM	Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader (GlobeNewswire)
10:01AM	Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Jan-16-24 04:01PM	Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL (GlobeNewswire) -6.94%
Jan-08-24 07:00AM	Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases (GlobeNewswire)
Jan-02-24 04:01PM	Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-23 05:01PM	CFO Houte Van Sells 10,906 Shares of Nurix Therapeutics Inc (GuruFocus.com) -6.41%
Dec-13-23 04:32PM	Judith A. Reinsdorf and Katherine M. Sandstrom Named to Toll Brothers Board of Directors (GlobeNewswire)
Dec-11-23 12:00PM	Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton's Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-04-23 04:01PM	Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) +8.68%
Nov-07-23 04:01PM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
09:00AM	Loading…
Nov-02-23 09:00AM	Nurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-01-23 04:01PM	Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial (GlobeNewswire)
Oct-18-23 09:35AM	Down -34.9% in 4 Weeks, Here's Why Nurix Therapeutics, Inc. (NRIX) Looks Ripe for a Turnaround (Zacks) -13.16%
Oct-14-23 06:01AM	Nurix Therapeutics Inc (NRIX) Reports Q3 Fiscal 2023 Financial Results (GuruFocus.com)
Oct-12-23 05:15PM	Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -6.03%
04:01PM	Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Oct-11-23 07:09AM	Nurix (NRIX) to Report Q3 Earnings: What's in Store? (Zacks)
Oct-05-23 09:35AM	Nurix Therapeutics, Inc. (NRIX) Loses -20.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Oct-04-23 09:35AM	Nurix Therapeutics, Inc. (NRIX) Loses -19.36% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Sep-28-23 10:00AM	Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Sep-20-23 09:30AM	Nurix Therapeutics, Inc. (NRIX) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks)
Sep-15-23 12:00PM	Nurix Therapeutics, Inc. (NRIX) Upgraded to Buy: Here's What You Should Know (Zacks)
09:55AM	Wall Street Analysts Think Nurix Therapeutics, Inc. (NRIX) Could Surge 215.32%: Read This Before Placing a Bet (Zacks)
Sep-11-23 12:10PM	Nurix (NRIX) Stock Increases 9% in a Month: Here's Why (Zacks)
Sep-08-23 05:32AM	Nurix Therapeutics, Inc. (NRIX) Soars 8.3%: Is Further Upside Left in the Stock? (Zacks) +5.23%
Sep-07-23 07:00AM	Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics (GlobeNewswire) +8.32%
Aug-31-23 10:12PM	11 Cheap Small-Cap Stocks to Buy Before the Next Breakout (Insider Monkey)
04:01PM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-02-23 05:01AM	Insider Sell: Gwenn Hansen Sells 1,884 Shares of Nurix Therapeutics Inc (GuruFocus.com)
Jul-24-23 09:55AM	Wall Street Analysts Believe Nurix Therapeutics, Inc. (NRIX) Could Rally 195.93%: Here's is How to Trade (Zacks)
Jul-15-23 08:12AM	Nurix Therapeutics Second Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Jul-13-23 05:15PM	Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-11-23 10:00AM	Swedish Orphan Biovitrum (BIOVF) Earnings Expected to Grow: Should You Buy? (Zacks)
Jun-29-23 10:00AM	Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jun-14-23 07:00AM	Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications (GlobeNewswire)
May-25-23 06:28AM	Nurix Therapeutics (NASDAQ:NRIX) shareholders have earned a 25% return over the last year (Simply Wall St.)
May-24-23 09:55AM	Does Nurix Therapeutics, Inc. (NRIX) Have the Potential to Rally 192.09% as Wall Street Analysts Expect? (Zacks)
May-09-23 04:01PM	Nurix Therapeutics to Participate in the 2023 RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +5.21%
May-04-23 09:55AM	Wall Street Analysts Predict a 233.33% Upside in Nurix Therapeutics, Inc. (NRIX): Here's What You Should Know (Zacks)
Apr-19-23 06:05AM	Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 30% Price Boost Is Out Of Tune With Revenues (Simply Wall St.)
Apr-18-23 09:55AM	How Much Upside is Left in Nurix Therapeutics, Inc. (NRIX)? Wall Street Analysts Think 134.94% (Zacks) -11.90%
Apr-17-23 02:30PM	Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance Mutations (GlobeNewswire) +8.67%
Apr-13-23 05:15PM	Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +12.43%
04:01PM	Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-11-23 04:01PM	Nurix Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-30-23 10:00AM	Will Nurix Therapeutics, Inc. (NRIX) Report Negative Q1 Earnings? What You Should Know (Zacks)
Mar-21-23 10:05AM	Nurix's (NRIX) Stock Up Due to License Option Exercise by Gilead (Zacks)
03:49AM	Strength Seen in Nurix Therapeutics, Inc. (NRIX): Can Its 5.7% Jump Turn into More Strength? (Zacks)
Mar-20-23 12:17PM	Gilead Exercises First License Option Under Agreement With Nurix Therapeutics (Benzinga) +5.66%
09:00AM	Nurixs stock rallies on Gileads option (MarketWatch)
08:30AM	Gilead Exercises Option to License Nurixs IRAK4 Targeted Protein Degrader Development Candidate, NX-0479 (GlobeNewswire)
Mar-17-23 09:22AM	Is Nurix Therapeutics (NASDAQ:NRIX) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Mar-14-23 04:45PM	Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting (GlobeNewswire)
Mar-06-23 04:01PM	Nurix Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-27-23 11:57AM	Down More Than 40%: 2 Strong Buy Stocks That Are Too Cheap to Ignore (TipRanks)
Feb-09-23 05:35PM	Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:15PM	Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-08-23 04:01PM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.03%
Jan-09-23 09:55AM	Bears are Losing Control Over Nurix Therapeutics, Inc. (NRIX), Here's Why It's a 'Buy' Now (Zacks) -6.39%
08:35AM	Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities (GlobeNewswire)
Jan-04-23 07:01AM	Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-28-22 09:35AM	After Plunging -15.8% in 4 Weeks, Here's Why the Trend Might Reverse for Nurix Therapeutics, Inc. (NRIX) (Zacks)
Dec-15-22 04:01PM	Nurix Therapeutics Announces Clearance of Investigational New Drug Application for NX-5948 Supporting Plans to Expand Enrollment to U.S. Clinical Sites (GlobeNewswire)
Dec-12-22 05:30PM	Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
08:09AM	Shareholders in Nurix Therapeutics (NASDAQ:NRIX) are in the red if they invested a year ago (Simply Wall St.)
Dec-07-22 04:01PM	Nurix Therapeutics Announces Webcast to Review Data from its Phase 1 Clinical Trial of BTK Degrader, NX-2127, Presented at the 64th American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-10-22 09:00AM	Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies (GlobeNewswire) +14.42%
09:00AM	Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in (GlobeNewswire)
Nov-04-22 09:55AM	Wall Street Analysts Think Nurix Therapeutics, Inc. (NRIX) Could Surge 187%: Read This Before Placing a Bet (Zacks)
Nov-03-22 09:00AM	Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-02-22 04:01PM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-26-22 07:00AM	Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkins Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit (GlobeNewswire)
Oct-19-22 10:57PM	Cathie Wood Buys Little-Known Pharma Firms Shares for Two Weeks (Bloomberg) -5.10%
09:00AM	Nurix Therapeutics Announces Presentations at the 5th Annual Targeted Protein Degradation (TPD) Summit (GlobeNewswire)
Oct-08-22 08:30AM	We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate (Simply Wall St.)
Oct-06-22 05:15PM	Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -6.49%
04:01PM	Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
Oct-05-22 08:00AM	Nurix Therapeutics Announces Six Poster Presentations at the Upcoming Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire) -5.11%
Sep-20-22 09:48AM	Cathie Wood is Buying These 10 Growth Stocks (Insider Monkey) -11.63%

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rape, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
van Houte Hans	Chief Financial Officer	Feb 16 '24	Sale	10.02	6,812	68,223	68,333	Feb 16 07:20 PM
van Houte Hans	Chief Financial Officer	Jan 30 '24	Option Exercise	0.00	4,886	0	76,816	Jan 30 06:53 PM
Hansen Gwenn	Chief Scientific Officer	Jan 30 '24	Option Exercise	0.00	5,207	0	38,736	Jan 30 06:52 PM
Ring Christine	Chief Legal Officer	Jan 30 '24	Option Exercise	0.00	3,924	0	19,187	Jan 30 06:52 PM
Hansen Gwenn	Chief Scientific Officer	Jan 30 '24	Sale	7.99	2,334	18,649	36,402	Jan 30 06:52 PM
Ring Christine	Chief Legal Officer	Jan 30 '24	Sale	7.99	1,760	14,063	17,427	Jan 30 06:52 PM
van Houte Hans	Chief Financial Officer	Jan 30 '24	Sale	7.99	1,671	13,352	75,145	Jan 30 06:53 PM
van Houte Hans	Chief Financial Officer	Dec 20 '23	Sale	10.00	3,541	35,421	71,930	Dec 21 05:19 PM
van Houte Hans	Chief Financial Officer	Dec 19 '23	Sale	10.00	10,906	109,093	75,471	Dec 20 04:55 PM
Hansen Gwenn	Chief Scientific Officer	Oct 31 '23	Sale	5.20	1,633	8,487	33,529	Nov 01 04:40 PM
Ring Christine	Chief Legal Officer	Oct 31 '23	Sale	5.20	1,232	6,403	15,263	Nov 01 04:40 PM
van Houte Hans	Chief Financial Officer	Oct 31 '23	Sale	5.20	1,080	5,613	86,377	Nov 01 04:41 PM
van Houte Hans	Chief Financial Officer	Oct 30 '23	Option Exercise	0.00	4,886	0	87,457	Nov 01 04:41 PM
Hansen Gwenn	Chief Scientific Officer	Oct 30 '23	Option Exercise	0.00	5,207	0	35,162	Nov 01 04:40 PM
Ring Christine	Chief Legal Officer	Oct 30 '23	Option Exercise	0.00	3,924	0	16,495	Nov 01 04:40 PM
Hansen Gwenn	Chief Scientific Officer	Jul 31 '23	Sale	9.65	1,884	18,189	29,955	Aug 01 04:26 PM
Ring Christine	General Counsel	Jul 31 '23	Sale	9.65	1,420	13,710	12,544	Aug 01 04:27 PM
van Houte Hans	Chief Financial Officer	Jul 31 '23	Sale	9.65	1,245	12,020	82,571	Aug 01 04:28 PM
van Houte Hans	Chief Financial Officer	Jul 30 '23	Option Exercise	0.00	4,886	0	83,816	Aug 01 04:28 PM
Ring Christine	General Counsel	Jul 30 '23	Option Exercise	0.00	3,924	0	13,964	Aug 01 04:27 PM
Hansen Gwenn	Chief Scientific Officer	Jul 30 '23	Option Exercise	0.00	5,207	0	31,839	Aug 01 04:26 PM
Hansen Gwenn	Chief Scientific Officer	May 01 '23	Sale	9.88	1,136	11,219	26,632	May 02 04:31 PM
van Houte Hans	Chief Financial Officer	May 01 '23	Sale	9.88	721	7,121	78,930	May 02 04:33 PM
Ring Christine	General Counsel	May 01 '23	Sale	9.88	682	6,736	10,040	May 02 04:32 PM
Wolff Stefani	EVP and COO	May 01 '23	Sale	9.88	342	3,378	6,113	May 02 04:33 PM
van Houte Hans	Chief Financial Officer	Apr 30 '23	Option Exercise	0.00	2,886	0	79,651	May 02 04:33 PM
Ring Christine	General Counsel	Apr 30 '23	Option Exercise	0.00	1,924	0	10,722	May 02 04:32 PM
Wolff Stefani	EVP and COO	Apr 30 '23	Option Exercise	0.00	962	0	6,455	May 02 04:33 PM
Hansen Gwenn	Chief Scientific Officer	Apr 30 '23	Option Exercise	0.00	3,206	0	27,768	May 02 04:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NRIX

Nurix Therapeutics Inc

Upgrade your FINVIZ experience